Are there any common ingredients between Shingrix (recombinant zoster vaccine) and COVID‑19 vaccines, given the patient may have had a drug‑induced liver injury from Shingrix?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Common Ingredients Between Shingrix and COVID-19 Vaccines

Yes, there is a critical shared ingredient: polysorbate 80 is present in Shingrix and is structurally related to polyethylene glycol (PEG) found in mRNA COVID-19 vaccines, creating potential cross-reactivity risk for your patient with suspected Shingrix-induced DILI.

Key Shared Components

Polysorbate 80 in Shingrix

According to the FDA label, Shingrix contains 0.08 mg of polysorbate 80 per dose 1. This excipient is used as a stabilizer in the vaccine formulation.

PEG and Polysorbate in COVID-19 Vaccines

The vaccine ingredients differ by platform 2:

  • mRNA vaccines (Pfizer/BioNTech, Moderna): Contain polyethylene glycol (PEG) in lipid nanoparticles to stabilize the mRNA
  • Adenoviral vector vaccines (J&J, AstraZeneca): Contain polysorbate 80

Clinical Significance for Your Patient

Cross-Reactivity Risk

Polysorbate and PEG are structurally similar compounds that can trigger cross-reactive immune responses 2. If your patient developed DILI from Shingrix (which contains polysorbate 80), there are two critical considerations:

  1. Adenoviral vector COVID vaccines (J&J) contain the same polysorbate 80 and should likely be avoided
  2. mRNA COVID vaccines contain PEG, which may cross-react with polysorbate antibodies, though the risk is less direct

Documented Liver Injury Patterns

COVID-19 vaccines have documented hepatotoxicity, typically presenting as autoimmune-like hepatitis 3, 4, 5:

  • Occurs with both mRNA and viral vector platforms
  • Can present as transient enzyme elevation or persistent autoimmune hepatitis
  • Most cases respond to corticosteroids
  • Rare but clear association established

Practical Recommendation Algorithm

For a patient with suspected Shingrix-induced DILI:

  1. Confirm the DILI diagnosis from Shingrix before proceeding (temporal relationship, liver enzyme pattern, exclusion of other causes)

  2. If DILI confirmed:

    • Avoid J&J/AstraZeneca vaccines (contain identical polysorbate 80)
    • Consider allergy testing for polysorbate and PEG before any COVID vaccination 2
    • If testing unavailable or positive, extended observation (30-60 minutes) post-vaccination is essential

  3. If mRNA vaccine chosen (Pfizer/Moderna):

    • Baseline liver function tests before vaccination
    • Monitor liver enzymes at 2-4 weeks post-vaccination
    • Educate patient on symptoms of hepatitis (jaundice, dark urine, right upper quadrant pain)
    • Lower threshold for hepatology referral if any enzyme elevation occurs

  4. Document vaccination history explicitly during any future DILI causality assessment, as patients often don't report vaccinations 5

Important Caveats

  • The mechanism of Shingrix DILI may differ from COVID vaccine hepatotoxicity (Shingrix contains unique adjuvants AS01B with MPL and QS-21 1)
  • However, the shared polysorbate component creates a plausible immunologic link
  • The benefits of COVID vaccination likely outweigh risks even in this scenario, but informed consent and monitoring are essential
  • Consider involving hepatology and allergy/immunology for shared decision-making

References

Related Questions

Does Shingrix (recombinant varicella‑zoster glycoprotein E vaccine) contain any components that are also present in seasonal influenza vaccines or COVID‑19 vaccines, given the patient experienced drug‑induced liver injury after Shingrix and is hesitant to receive another vaccine?
In a patient with primary sclerosing cholangitis and inflammatory bowel disease who developed drug‑induced liver injury after receiving the recombinant zoster vaccine (Shingrix), should they avoid influenza and COVID‑19 vaccines, and what is the likelihood of a similar reaction?
Is the AS01B adjuvant used in any other vaccines, and what other components of the recombinant zoster vaccine (Shingrix) could have caused the patient’s drug‑induced liver injury?
In a 48-year-old patient who has just had shingles, should the recombinant zoster vaccine (Shingrix) be administered immediately or wait until age 50?
Can a patient with an allergy to the Shingrix (recombinant varicella‑zoster virus glycoprotein E) vaccine safely receive valacyclovir?
In a 78-year-old woman with a puncture wound infection of the right index finger, what is the most appropriate antibiotic therapy?
What are degenerative changes of the spine?
What is the appropriate metronidazole dose for a child weighing 32.32 kg?
What is the acute treatment for a transient ischemic attack (TIA)?
What is the appropriate ondansetron (Zofran) dose for a child weighing 32.32 kg?
A patient receiving amoxicillin/clavulanate (Augmentin) for a skin infection develops a streptococcal infection with only one dose of the current antibiotic remaining; what is the appropriate treatment for the streptococcal infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.